id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2006-P-0007-0055,FDA,FDA-2006-P-0007,Tab 3 re Supplement from ViroPharma Incorporated,Supporting & Related Material,Background Material,2014-01-31T05:00:00Z,2014,1,,,2014-02-01T00:32:45Z,,0,0,0900006480441478
FDA-2006-P-0007-0053,FDA,FDA-2006-P-0007,Supplement from ViroPharma Incorporated,Other,Supplement (SUP),2014-01-31T05:00:00Z,2014,1,2014-01-31T05:00:00Z,,2014-01-31T23:37:55Z,,0,0,0900006480924c45
FDA-2006-P-0007-0062,FDA,FDA-2006-P-0007,Comment from D. Robertson re Conference Call Transcript,Supporting & Related Material,Background Material,2014-01-31T05:00:00Z,2014,1,,,2014-02-01T00:52:43Z,,0,0,0900006480441492
FDA-2006-P-0007-0056,FDA,FDA-2006-P-0007,Comment from Diane Robertson,Supporting & Related Material,Electronic Comment (EC),2014-01-31T05:00:00Z,2014,1,,,2014-02-01T00:32:52Z,,0,0,0900006480441494